Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 201–300 of 1,003
Rabal, O., Sánchez-Arias, J. A., Cuadrado‐Tejedor, M., de Miguel, I., Pérez-González, M., García, C., Ugarte, A., de Mendoza, A. E., Sáez, E., Espelosin, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00908 · Cited by 94
The emerging role of regulatory cell-based therapy in autoimmune disease
Ghobadinezhad, F., Ebrahimi, N., Mozaffari, F., Moradi, N., Beiranvand, S., Pournazari, M., Rezaei‐Tazangi, F., Khorram, R., Afshinpour, M., Robino, R. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1075813 · Cited by 99
Liu, J., Livingston, M. J., Dong, G., Tang, C., Su, Y., Wu, G., Yin, X., & Dong, Z. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0374-7 · Cited by 89
“C57BL/6 mice were divided into five groups for the following treatment: (1) saline (n= 8), (2) a single dose of cisplatin (30 mg/kg, i.”
MethodHistones: The critical players in innate immunity
Li, X., Ye, Y., Peng, K., Zeng, Z., Chen, L., & Zeng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030610 · Cited by 112
Zhou, H., Cai, Y., Liu, D., Li, M., Sha, Y., Zhang, W., Wang, K., Gong, J., Tang, N., Huang, A., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12447 · Cited by 85
Pinho, B. R., Reis, S., Guedes-Dias, P., Leitão-Rocha, A., Quintas, C., Valentão, P., Andrade, P. B., Santos, M. M., & Oliveira, J. M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.024 · Cited by 92
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 95
Activity-Guided Design of HDAC11-Specific Inhibitors
Son, S. I., Cao, J., Zhu, C., Miller, S. P., & Lin, H. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00292 · Cited by 87
Histone Deacetylases and Their Inhibition in Candida Species
Garnaud, C., Champleboux, M., Maubon, D., Cornet, M., & Govin, J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01238 · Cited by 96
Bug, G., Burchert, A., Wagner, E.-M., Kröger, N. M., Berg, T., Gueller, S., Metzelder, S., Wolf, A., Hünecke, S., Bader, P., et al. (2017) · Leukemia · doi:10.1038/leu.2017.242 · Cited by 89
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“The HDAC-inhibitors vorinostat and romidepsin have received FDA approval for cutaneous T-cell lymphoma, and the large number of clinical trials with these substances has been summarized by others (Copeland et al., 2009; Falkenberg & Johnstone, 2014; Johnstone, 2002).”
BackgroundThe emerging roles of HDACs and their therapeutic implications in cancer
Hai, R., Yang, D., Zheng, F., Wang, W., Han, X., Bode, A. M., & Luo, X. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175216 · Cited by 79
The role of epigenomics in personalized medicine
Kronfol, M. M., Dozmorov, M. G., Huang, R., Slattum, P. W., & McClay, J. L. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1284557 · Cited by 87
Cho, J.-H., Dimri, M., & Dimri, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624361 · Cited by 88
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
Kikuchi, S., Suzuki, R., Ohguchi, H., Yoshida, Y., Lu, D., Cottini, F., Jakubíková, J., Bianchi, G., Harada, T., Görgün, G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.83 · Cited by 88
Exploring the epigenetic drug discovery landscape
Prachayasittikul, V., Prathipati, P., Pratiwi, R., Phanus‐umporn, C., Malik, A. A., Schaduangrat, N., Seenprachawong, K., Wongchitrat, P., Supokawej, A., Prachayasittikul, V., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1295954 · Cited by 86
Acetylation and deacetylation in cancer stem-like cells
Liu, N., Li, S., Wu, N., & Cho, K. (2017) · Oncotarget · doi:10.18632/oncotarget.19167 · Cited by 84
“Aberrant recruitment of HDACs to specific promoters has been shown to be associated with carcinogenesis [56, 57].”
BackgroundBahl, S., & Seto, E. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03599-4 · Cited by 82
Núñez‐Álvarez, Y., & Suelves, M. (2021) · FEBS Journal · doi:10.1111/febs.15895 · Cited by 94
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 94
“DNA methylation supports dynamic gene expression, affecting the highly orchestrated trafficking and activation of tumor infiltrating lymphocytes [11,12].”
BackgroundValente, S., Mellini, P., Spallotta, F., Carafa, V., Nebbioso, A., Polletta, L., Carnevale, I., Saladini, S., Trisciuoglio, D., Gabellini, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01117 · Cited by 84
The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
Benito, E., Ramachandran, B., Schroeder, H., Schmídt, G., Urbanke, H., Burkhardt, S., Capece, V., Dean, C., & Fischer, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.202 · Cited by 92
miR-21-3p Regulates Influenza A Virus Replication by Targeting Histone Deacetylase-8
Xia, B., Lu, J., Wang, R., Yang, Z., Zhou, X., & Huang, P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00175 · Cited by 90
“HDACs play important roles in cancer, viral infection, neurological diseases and immune disorders (Falkenberg and Johnstone, 2014; Chakrabarti et al., 2015).”
BackgroundOsko, J. D., & Christianson, D. W. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00934 · Cited by 83
Azzali, E., Machado, D., Kaushik, A., Vacondio, F., Flisi, S., Cabassi, C. S., Lamichhane, G., Viveiros, M., Costantino, G., & Pieroni, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00793 · Cited by 86
Omar, S. H., Scott, C., Hamlin, A. S., & Obied, H. K. (2018) · Fitoterapia · doi:10.1016/j.fitote.2018.05.011 · Cited by 89
Development of a Potent and Selective HDAC8 Inhibitor
Ingham, O. J., Paranal, R. M., Smith, W. B., Escobar, R. A., Yueh, H., Snyder, T., Porco, J. A. J., Bradner, J. E., & Beeler, A. B. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00239 · Cited by 79
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective
Tsilimigras, D. I., Ntanasis‐Stathopoulos, I., Moris, D., Spartalis, E. D., & Pawlik, T. M. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2018.07.015 · Cited by 80
Recent Applications of Diazirines in Chemical Proteomics
Halloran, M. W., & Lumb, J. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805004 · Cited by 84
Reprogramming of macrophages — new opportunities for therapeutic targeting
Schultze, J. L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.007 · Cited by 86
Wu, H., Medeiros, L. J., & Young, K. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.004 · Cited by 84
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0598-5 · Cited by 78
An Expanding Repertoire of Protein Acylations
Xu, Y., Shi, Z., & Bao, L. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100193 · Cited by 81
“hibitors, and hydrazide-based HDACis (76, 77).”
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4579 · Cited by 78
Self-citationNiederberger, E., Resch, E., Parnham, M. J., & Geißlinger, G. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.68 · Cited by 83
Photoorganocatalytic One‐Pot Synthesis of Hydroxamic Acids from Aldehydes
Papadopoulos, G. N., & Kokotos, C. G. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600333 · Cited by 78
Huang, W., Chen, Y., Fedorov, A., Li, X., Jajamovich, G. H., Malyarenko, D. I., Aryal, M. P., LaViolette, P. S., Oborski, M. J., O’Sullivan, F., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00027 · Cited by 82
Koeneke, E., Witt, O., & Oehme, I. (2015) · Cells · doi:10.3390/cells4020135 · Cited by 75
Zhu, B., Shang, B.-Y., Li, L., & Zhen, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5041 · Cited by 81
Rational targeting of immunosuppressive neutrophils in cancer
Zhao, Y., Rahmy, S., Liu, Z., Zhang, C., & Lü, X. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107556 · Cited by 80
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 79
Hou, H., & Tien, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00674-7 · Cited by 108
Eichner, L. J., Curtis, S. D., Brun, S. N., McGuire, C. K., Gushterova, I., Baumgart, J. T., Trefts, E., Ross, D. S., Rymoff, T. J., & Shaw, R. J. (2023) · Science Advances · doi:10.1126/sciadv.add3243 · Cited by 75
“…waning, which has been conjectured to be due to limiting toxicity from current agents inhibiting multiple HDAC family members, as well as lack of insights into the optimal clinical contexts where HDAC inhibitors may synergize with other currently approved or in-develop-ment therapeutics ( 54 ).”
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., & Le Tourneau, C. (2021) · Cancers · doi:10.3390/cancers14010066 · Cited by 75
“This can induce a range of cellular and molecular effects, including antitumor effect, such as tumor cell death, cell cycle arrest, senescence, differentiation, and increased tumor immunogenicity highlighting the function of HDAC inhibitors as anti-cancer drugs [23].”
BackgroundGrunert, M., Dorn, C., Cui, H., Dunkel, I., Schulz, K., Schoenhals, S., Sun, W., Berger, F. F., Chen, W., & Sperling, S. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw195 · Cited by 79
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8
Porter, N. J., & Christianson, D. W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00330 · Cited by 78
Diverse nucleosome Site-Selectivity among histone deacetylase complexes
Wang, Z. A., Millard, C. J., Lin, C., Gurnett, J. E., Wu, M., Lee, K., Fairall, L., Schwabe, J. W. R., & Cole, P. A. (2020) · eLife · doi:10.7554/elife.57663 · Cited by 78
Sada, N., Fujita, Y., Mizuta, N., Ueno, M., Furukawa, T., & Yamashita, T. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02897-w · Cited by 71
Romidepsin targets multiple survival signaling pathways in malignant T cells
Valdez, B. C., Brammer, J. E., Li, Y., Murray, D. L., Liu, Y., Hosing, C. M., Nieto, Y. L., Champlin, R. E., & Andersson, B. S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.83 · Cited by 78
Smyd3-associated regulatory pathways in cancer
Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 85
Epigenetic Alterations in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Doody, K. M., Bottini, N., & Firestein, G. S. (2017) · Epigenomics · doi:10.2217/epi-2016-0151 · Cited by 75
Lee, H., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K., Lin, T. E., Yeh, T., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 77
Histone Acylation beyond Acetylation: Terra Incognita in Chromatin Biology.
Rousseaux, S., & Khochbin, S. (2015) · PubMed Central · doi:10.22074/cellj.2015.506 · Cited by 93
Fluorescent Probes for Single-Step Detection and Proteomic Profiling of Histone Deacetylases
Xie, Y., Ge, J., Lei, J. H., Peng, B., Zhang, H., Wang, D., Pan, S., Chen, G., Chen, L., Wang, Y., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b07334 · Cited by 74
Lu, Y., Stuart, J. H., Talbot-Cooper, C., Singh, S. A., Huntly, B. J. P., Smid, A. I., Snowden, J. S., Dupont, L., & Smith, G. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816399116 · Cited by 76
“Conversely, HDAC11 negatively regulates type I IFN signaling by controlling lysine fatty acylation of serine hydroxymethyltransferase 2 (SHMT2) and thereby the surface level of type I IFN receptor 1 (20).”
BackgroundInfluentialInnovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Computer-Aided Drug Design in Epigenetics
Lu, W., Zhang, R., Jiang, H., Zhang, H., & Luo, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00057 · Cited by 81
“So far, five epi-drugs targeting HDACs have been approved for clinical use and other HDAC inhibitors like entinostat and CUDC-907 have entered into clinical trials for advanced cancer treatment (Falkenberg and Johnstone, 2014; Li and Seto, 2016).”
BackgroundKiweler, N., Brill, B., Wirth, M., Breuksch, I., Laguna, T., Dietrich, C., Strand, S., Schneider, G., Groner, B., Butter, F., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2229-5 · Cited by 78
Huang, Z., Zhou, W., Li, Y., Cao, M., Wang, T., Ma, Y., Guo, Q., Wang, X., Zhang, C., Zhang, C., et al. (2018) · Theranostics · doi:10.7150/thno.26627 · Cited by 72
“Histone deacetylases (HDACs) regulate chromatin remodelling, gene transcription, and the activity of partner proteins, controlling cell growth, cell cycle regulation, DNA mismatch repair, proliferation and apoptosis [5, 6].”
BackgroundPeng, X., Chen, J., Li, L., Sun, Z., Liu, J., Ren, Y., Huang, J., & Chen, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00413 · Cited by 74
Curcio, A., Rocca, R., Alcaro, S., & Artese, A. (2024) · Pharmaceuticals · doi:10.3390/ph17050620 · Cited by 80
BET Bromodomain as a Target of Epigenetic Therapy
Noguchi‐Yachide, T. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00225 · Cited by 74
Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme
Wang, G., Wang, J., Fu, X., Guang, R., & To, S.-S. T. (2016) · Oncology Reports · doi:10.3892/or.2016.5309 · Cited by 82
Zhang, Y., Zhu, D., Wei, Y., Wu, Y., Cui, W., Liuqin, L., Fan, G., Yang, Q., Wang, Z., Xu, Z., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.022 · Cited by 71
Hypothalamic epigenetics driving female puberty
Toro, C. A., Aylwin, C. F., & Lomniczi, A. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12589 · Cited by 78
Li, D., Zhang, L., Zhang, Y., Guan, S., Gong, X., & Wang, X. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-05258-z · Cited by 77
Duan, J., Wang, C., Yuan, Y., Hui, Z., Zhang, H., Mao, N., Zhang, P., Sun, B., Jing, L., Zhang, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00090 · Cited by 69
Epigenomic regulation of host–microbiota interactions
Alenghat, T., & Artis, D. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.007 · Cited by 76
Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis
Neele, A. E., den Bossche, J. V., Hoeksema, M. A., & de Winther, M. P. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.101 · Cited by 79
Shi, M., Lu, X., Zhang, J., Diao, H., Li, G., Xu, L., Wang, T., Wei, J., Meng, W., Ma, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8033 · Cited by 74
ALS and FTD: an epigenetic perspective
Belzil, V., Katzman, R. B., & Petrucelli, L. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1587-4 · Cited by 79
Ding, N., You, A., Tian, W., Gu, L., & Deng, D. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45886 · Cited by 73
Xu, B., Zhang, Q., Hu, X., Li, Q., Sun, T., Li, W., Ouyang, Q., Wang, J., Tong, Z., Yan, M., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.001 · Cited by 74
Alam†, M. S., Getz, M., & Haldar, K. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9407 · Cited by 72
Therapeutic significance of quinolines: a patent review (2013-2015)
Hussaini, S. M. A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1216545 · Cited by 77
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 82
“Furthermore, some HDAC families serve as subunits of large protein complexes and can promote carcinogenesis (76, 77).”
BackgroundPeng, X., Li, L., Chen, J., Ren, Y., Liu, J., Yu, Z., Cao, H., & Chen, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01863 · Cited by 70
Pompo, G. D., Salerno, M., Rotili, D., Valente, S., Zwergel, C., Avnet, S., Lattanzi, G., Baldini, N., & Mai, A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00126 · Cited by 68
Milcovich, G., Lettieri, S., Antunes, F. E., Medronho, B., Fonseca, A. C., Coelho, J. F. J., Marizza, P., Perrone, F., Farra, R., Dapas, B., et al. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.009 · Cited by 80
Zhang, S., Fujita, Y., Matsuzaki, R., & Yamashita, T. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0543-8 · Cited by 68
Soria-Castro, R., Schcolnik‐Cabrera, A., Rodríguez-López, G. M., Campillo-Navarro, M., Puebla‐Osorio, N., Estrada-Parra, S. A., Estrada‐García, I., Chacón‐Salinas, R., & Chávez-Blanco, A. D. (2019) · Journal of Immunology Research · doi:10.1155/2019/9678098 · Cited by 74
“VPA induces the epigenetic inhibition of HDACs categorized as class Ia (HDAC1 and HDAC2), class Ib (HDAC3), class Ic (HDAC8), and class IIa (HDAC4, HDAC5, and HDAC7), leading to an increase in the acetylation of histones H2, H3, and H4, which modify the expression of genes associated with apoptosis, cell cycle, cell d…”
BackgroundRen, Y., Li, S., Zhu, R., Wan, C., Song, D., Zhu, J., Cai, G., Long, S., Kong, L., & Yu, W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00136 · Cited by 69
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 83
Raynal, N. J. ‐., Costa, E. M. D., Lee, J. T., Gharibyan, V., Ahmed, S., Zhang, H., Sato, T., Malouf, G. G., & Issa, J. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0588 · Cited by 67
Chen, X., Zhao, S., Li, H., Wang, X., Geng, A., Hao, C., Lu, T., Chen, Y., & Zhu, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.032 · Cited by 69
Linking Telomere Regulation to Stem Cell Pluripotency
Liu, L. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.10.007 · Cited by 75
Synthesis and evaluation of novel dual BRD4/HDAC inhibitors
Amemiya, S., Yamaguchi, T., Hashimoto, Y., & Noguchi‐Yachide, T. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.043 · Cited by 68
An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
Cao, Z., Kon, N., Liu, Y., Xu, W., Wen, J., Yao, H., Zhang, M., Wu, Z., Yan, X., Zhu, W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4148 · Cited by 70
“So far, more than 350 clinical trials have been performed by testing HDACi per se or the combination of HDACi with other types of therapeutic strategy in the treatment of various malignancies (41), and some HDACis such as vorinostat and romidepsin (also known as suberanilohydroxamic acid and depsipeptide, respectively…”
BackgroundEpigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 73
Wu, M., Hayward, D., Kalin, J. H., Song, Y., Schwabe, J. W. R., & Cole, P. A. (2018) · eLife · doi:10.7554/elife.37231 · Cited by 66
“31 HDAC1 is a Class I HDAC Zn hydrolase and has a broad range of targeted acetyl-lysine (Kac) sites in 32 histones and non-histone proteins (Cole, 2008; Falkenberg & Johnstone, 2014; Taunton et al., 1996).”
BackgroundTargeting Chromatin Remodeling for Cancer Therapy
Kaur, J., Daoud, A., & Eblen, S. T. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190215112915 · Cited by 73
Hideshima, T., Cottini, F., Ohguchi, H., Jakubíková, J., Görgün, G., Mimura, N., Tai, Y., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.38 · Cited by 66
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
Wang, Z., TANG, F., Hu, P., Wang, Y., Gong, J., Sun, S., & Xie, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4811 · Cited by 71
Ma, X., Wang, J., Wang, J., Charles, X., Gao, X., Patriub, V., & Sklar, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13270 · Cited by 74
Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Pojani, E., & Barlocco, D. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200203113926 · Cited by 65
Therapeutic Options for Retinoblastoma
Mendoza, P. R., & Grossniklaus, H. E. (2016) · Cancer Control · doi:10.1177/107327481602300203 · Cited by 69
Singleton, W., Collins, A., Bienemann, A., Killick-Cole, C. L., Haynes, H. R., Asby, D. J., Butts, C. P., Wyatt, M., Barua, N. U., & Gill, S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s125300 · Cited by 70
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.